Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jussi Sane is active.

Publication


Featured researches published by Jussi Sane.


Emerging Infectious Diseases | 2014

Epidemic of mumps among vaccinated persons, The Netherlands, 2009-2012.

Jussi Sane; Sigrid Gouma; Marion Koopmans; Hester E. de Melker; Corien Swaan; Rob van Binnendijk; Susan Hahné

To analyze the epidemiology of a nationwide mumps epidemic in the Netherlands, we reviewed 1,557 notified mumps cases in persons who had disease onset during September 1, 2009–August 31, 2012. Seasonality peaked in spring and autumn. Most case-patients were males (59%), 18–25 years of age (67.9%), and vaccinated twice with measles-mumps-rubella vaccine (67.7%). Nearly half (46.6%) of cases occurred in university students or in persons with student contacts. Receipt of 2 doses of vaccine reduced the risk for orchitis, the most frequently reported complication (vaccine effectiveness [VE] 74%, 95% CI 57%–85%); complications overall (VE 76%, 95% CI 61%–86%); and hospitalization (VE 82%, 95% CI 53%–93%). Over time, the age distribution of case-patients changed, and proportionally more cases were reported from nonuniversity cities (p<0.001). Changes in age and geographic distribution over time may reflect increased immunity among students resulting from intense exposure to circulating mumps virus.


Reviews in Medical Virology | 2016

Sindbis virus as a human pathogen-epidemiology, clinical picture and pathogenesis.

Samuel Adouchief; Teemu Smura; Jussi Sane; Olli Vapalahti; Satu Kurkela

Sindbis virus (SINV; family Togaviridae, genus Alphavirus) is an enveloped RNA virus widely distributed in Eurasia, Africa, Oceania and Australia. SINV is transmitted among its natural bird hosts via mosquitoes. Human disease caused by SINV infection has been reported mainly in South Africa and in Northern Europe. Vector mosquito abundance affects the annual incidence of SINV infections with occasional outbreaks of up to 1500 patients. Symptoms include fever, malaise, rash and musculoskeletal pain. In a significant portion of patients the debilitating musculoskeletal symptoms persist for years. Chronic disease after SINV infection shares many features with autoimmune diseases. Currently there is no specific treatment available. Recently SINV infections have been detected outside the previously known distribution range. In this article we will summarize the current knowledge on epidemiology, clinical disease and pathogenesis of SINV infection in man. Copyright


WOS | 2016

Sindbis virus as a human pathogenepidemiology, clinical picture and pathogenesis

Samuel Adouchief; Teemu Smura; Jussi Sane; Olli Vapalahti; Satu Kurkela

Sindbis virus (SINV; family Togaviridae, genus Alphavirus) is an enveloped RNA virus widely distributed in Eurasia, Africa, Oceania and Australia. SINV is transmitted among its natural bird hosts via mosquitoes. Human disease caused by SINV infection has been reported mainly in South Africa and in Northern Europe. Vector mosquito abundance affects the annual incidence of SINV infections with occasional outbreaks of up to 1500 patients. Symptoms include fever, malaise, rash and musculoskeletal pain. In a significant portion of patients the debilitating musculoskeletal symptoms persist for years. Chronic disease after SINV infection shares many features with autoimmune diseases. Currently there is no specific treatment available. Recently SINV infections have been detected outside the previously known distribution range. In this article we will summarize the current knowledge on epidemiology, clinical disease and pathogenesis of SINV infection in man. Copyright


The Journal of Infectious Diseases | 2011

Epidemic Sindbis Virus Infection in Finland: A Population-Based Case-Control Study of Risk Factors

Jussi Sane; Sandra Guedes; Jukka Ollgren; Satu Kurkela; Peter Klemets; Olli Vapalahti; Eija Kela; Outi Lyytikäinen; J. Pekka Nuorti

BACKGROUND Sindbis virus (SINV) is an arthropod-borne alphavirus that causes rash and arthritis. In Finland, epidemics occur cyclically, but factors associated with clinical SINV infection are largely unknown. We conducted a population-based case-control study during the epidemic year 2002. METHODS SINV cases were serologically confirmed and reported to the National Infectious Disease Registry. Five control subjects, matched for age, sex, and residence, were selected from the National Population Information System. Data were collected using a self-administered mail survey. Conditional logistic regression models were used to identify independent risk factors; missing data were addressed using Bayesian full-likelihood modeling. RESULTS A total of 337 case patients (58% female; age range, 1-94 y) and 934 control subjects were enrolled. Reported exposure to mosquito bites (matched odds ratio [mOR], 16.7; 95% confidence interval [CI], 9.1-33.4) and spending time in woods or marshland (mOR, 1.8; 95% CI, 1.3-2.5) were independently associated with SINV infection in the multivariable model. The population-attributable risk for mosquito bites was 87.2%. There were dose-response relations for increased number of insect bites (mOR, 23.8-72.5) and increased time spent in woods or marshland (mOR, 1.3-2.2). CONCLUSIONS Educating the public in endemic areas to avoid mosquito exposure and use protective measures remain important prevention measures for SINV infection.


Clinical Infectious Diseases | 2012

Clinical Sindbis Alphavirus Infection Is Associated With HLA-DRB1*01 Allele and Production of Autoantibodies

Jussi Sane; Satu Kurkela; Marja-Liisa Lokki; Aaro Miettinen; Tapani Helve; Antti Vaheri; Olli Vapalahti

BACKGROUND Sindbis virus (SINV) is a mosquito-borne alphavirus found in Eurasia, Africa, and Oceania. Clinical SINV infection, characterized by arthropathic disease that may persist for years, is primarily reported in Northern Europe where the disease has considerable public health importance in endemic areas. The aim of this study was to investigate the role of genetic factors in the susceptibility and outcome of SINV infection and to elucidate the association between SINV infection and autoimmunity. METHODS The study included 49 patients with serologically confirmed symptomatic SINV infection who were followed for 3 years after acute infection. Human leukocyte antigen (HLA) genes known to be associated with rheumatic and infectious diseases and complement C4 genes were determined in 35 patients. Furthermore, a set of autoantibodies was measured at the acute phase and 3 years after infection in 44 patients. RESULTS The frequency of DRB1*01 was significantly higher among patients with SINV infection than in the reference population (odds ratio, 3.3; 95% confidence interval, 1.7-6.5; P = .003). The DRB1*01 allele was particularly frequent in patients who at 3 years postinfection experienced joint manifestations. The frequency of rheumatoid factor at 3 years postinfection was 29.5% and had increased significantly (P = .02) during the 3-year period. In addition, antinuclear and antimitochondrial antibodies were present in serum 3 years postinfection with frequencies of 15.9% and 6.8%, respectively. CONCLUSIONS Our data show that symptomatic SINV infection is associated with the HLA system and that autoantibody titers are elevated in patients 3 years postinfection. These findings indicate that SINV-induced arthritis shares features with autoimmune diseases.


Emerging Infectious Diseases | 2017

Lyme Borreliosis in Finland, 1995–2014

Eeva Sajanti; Mikko J. Virtanen; Otto Helve; Markku Kuusi; Outi Lyytikäinen; Jukka Hytönen; Jussi Sane

We investigated the epidemiology of Lyme borreliosis (LB) in Finland for the period 1995–2014 by using data from 3 different healthcare registers. We reviewed data on disseminated LB cases from the National Infectious Diseases Register (21,051 cases) and the National Hospital Discharge Register (10,402 cases) and data on primary LB (erythema migrans) cases from the Register for Primary Health Care Visits (11,793 cases). Incidence of microbiologically confirmed disseminated LB cases increased from 7/100,000 population in 1995 to 31/100,000 in 2014. Incidence of primary LB cases increased from 44/100,000 in 2011 to 61/100,000 in 2014. Overall, cases occurred predominantly in women, and we observed a bimodal age distribution in all 3 registers. Our results clearly demonstrate that the geographic distribution of LB has expanded in Finland and underscore the importance of LB as an increasing public health concern in Finland and in northern Europe in general.


Eurosurveillance | 2016

Respiratory diphtheria in an asylum seeker from Afghanistan arriving to Finland via Sweden, December 2015.

Jussi Sane; Tiina Sorvari; Micael Widerström; Heikki Kauma; Ulla Kaukoniemi; Eveliina Tarkka; Taneli Puumalainen; Markku Kuusi; Mika Salminen; Outi Lyytikäinen

In December 2015, an asylum seeker originating from Afghanistan was diagnosed with respiratory diphtheria in Finland. He arrived in Finland from Sweden where he had already been clinically suspected and tested for diphtheria. Corynebacterium diphtheriae was confirmed in Sweden and shown to be genotypically and phenotypically toxigenic. The event highlights the importance of early case detection, rapid communication within the country and internationally as well as preparedness plans of diphtheria antitoxin availability.


Ticks and Tick-borne Diseases | 2017

Knowledge, attitudes, and practices regarding ticks and tick-borne diseases, Finland

Viktor Zöldi; Topi Turunen; Outi Lyytikäinen; Jussi Sane

Tick-borne encephalitis (TBE) and Lyme borreliosis (LB) are endemic in Finland, with tens and thousands of cases, respectively, reported annually. We performed a field survey to investigate peoples knowledge, attitudes and practices (KAP) regarding ticks, tick-borne diseases, and prevention strategies. The KAP were assessed using a pre-validated anonymous questionnaire consisting of 39 questions and statements. On two consecutive days in July 2016, convenience sampling was used in the cities of Parainen and Kotka, located in high-risk areas of tick-borne diseases, particularly of TBE. In attitudes and practices sections, each question was scored and analysed with ordered logistic regression model. In total, 101 individuals responded. The TBE vaccination rate among respondents was 40%. The best known preventive measures were having vaccination against TBE (88%), and wearing long sleeves and pants against ticks (81%). Two-thirds incorrectly identified the ring-like rash as a symptom of TBE. Of all respondents, 78% could not exclude that TBE can be treated with antibiotics; 55% that vaccine protects against LB; and 46% that it protects against ticks. The minority (14%) believed tick repellents to be effective. Among preventive behaviour, the quick removal of an attached tick was most frequently applied (97%). Repellents were used by 21% when visiting tick-infested areas. Significant associations were found between the vaccination status and having a correct belief that the vaccine protects against TBE (P<0.001) but not against ticks (P<0.05), or LB (P<0.001). KAP is a quick and easy tool to get a rough estimation on peoples awareness regarding ticks and tick-borne diseases. We identified gaps in knowledge and misbeliefs. Our results can be used in public health communication tools on tick-borne diseases, especially those on intervention strategies.


Emerging Infectious Diseases | 2018

Fatal Tick-Borne Encephalitis Virus Infections Caused by Siberian and European Subtypes, Finland, 2015

Teemu Smura; Kirsi Rantanen; Leena Kämppi; Jonas Kantonen; Mia Kero; Anu Jääskeläinen; Anne J. Jääskeläinen; Jussi Sane; Liisa Myllykangas; Anders Paetau; Olli Vapalahti

In most locations except for Russia, tick-borne encephalitis is mainly caused by the European virus subtype. In 2015, fatal infections caused by European and Siberian tick-borne encephalitis virus subtypes in the same Ixodes ricinus tick focus in Finland raised concern over further spread of the Siberian subtype among widespread tick species.


Vaccine | 2017

Decreased incidence of pertussis in young adults after the introduction of booster vaccine in military conscripts: Epidemiological analyses of pertussis in Finland, 1995-2015

Viktor Zöldi; Jussi Sane; Hanna Nohynek; Maria Virkki; Tuula Hannila-Handelberg; Jussi Mertsola

INTRODUCTION In 2005, in Finland, the whole-cell pertussis vaccine was replaced by acellular given at 3-5-12months, and boosters at 4 and 11-15years of age. From July 2012, military conscripts have been offered a pertussis booster dose. Conscription is mandatory for Finnish men, and >95% were 19-21years old when enrolled during 2012-2015. We describe the epidemiology of pertussis in Finland during 1995-2015, and show the indirect effect of the booster in conscripts on pertussis incidence in the Finnish population. MATERIALS AND METHODS We extracted data on laboratory confirmed notified pertussis cases from the National Infectious Diseases Register. We calculated annual incidence using as denominator population data and incidence rate ratios (IRR) using Poisson regression. RESULTS The overall pertussis incidence peaked in 2004 (31/100,000) and was lowest in 2015 (3.0/100,000), with 66 reported cases in <3months infants in 2004 versus 6 in 2015. The majority of the cases were female (59%) with a male-to-female case ratio of 1:1.5. Cases were spread throughout the year with highest incidence during August-February. Among the 19- to 21-year-olds in the general population, incidence decreased from 49/100,000 in 2011 to 0.51/100,000 in 2015 (IRR=0.01; 95%CI, 0.00-0.16). Among the same age group, comparing the 3.5-year period before and after July 2012, incidence decreased from 33/100,000 to 5.3/100,000 (IRR=0.16; 95%CI, 0.06-0.40) in males and from 16/100,000 to 5.0/100,000 (IRR=0.31; 95%CI, 0.11-0.84) in females. CONCLUSIONS Implementation of the pertussis booster dose in Finnish military conscripts was followed by a significant decrease in pertussis incidence both among the 19- to 21-year-old males and females, possibly reflecting herd immunity effect. Together with booster doses in adolescents this has resulted in low incidence in the whole population including infants. Our results support the implementation of the booster dose for conscripts. We recommend continuing monitoring pertussis epidemiology to optimize pertussis vaccination strategies in Finland.

Collaboration


Dive into the Jussi Sane's collaboration.

Top Co-Authors

Avatar

Outi Lyytikäinen

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar

Olli Vapalahti

Finnish Forest Research Institute

View shared research outputs
Top Co-Authors

Avatar

Markku Kuusi

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jukka Ollgren

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mia Kontio

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Mikko J. Virtanen

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Teemu Smura

University of Helsinki

View shared research outputs
Researchain Logo
Decentralizing Knowledge